GPR17 receptor modulators and their therapeutic implications: review of recent patents

References

• Fang Y, Kenakin T, Liu C. Editorial: orphan GPCRs as emerging drug targets. Front Pharmacol. 2015;6:295.
   PubMed Web of Science ®Google Scholar
• Shore DM, Reggio PH. The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front Pharmacol. 2015;6:69.
   PubMed Web of Science ®Google Scholar
• Civelli O. GPCR deorphanizations: the novel, the known and the unexpected transmitters. Trends Pharmacol Sci. 2005;26:15–19.
   PubMed Web of Science ®Google Scholar
• Raport CJ, Schweickart VL, Chantry D, et al. New members of the chemokine receptor gene family. Leukoc Biol. 1996;59:18–23.
   PubMed Web of Science ®Google Scholar
• Blasius R, Weber RG, Lichter P, et al. A novel orphan G protein-coupled receptor primarily expressed in the brain is localized on human chromosomal band 2q21. J Neurochem. 1998;70:1357–1365.
   PubMed Web of Science ®Google Scholar
• Ciana P, Fumagalli M, Trincavelli ML, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. Embo J. 2006;25:4615–4627.
   PubMed Web of Science ®Google Scholar
• Lecca D, Trincavelli ML, Gelosa P, et al. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One. 2008;3(10):e3579.
   PubMed Web of Science ®Google Scholar
• Pugliese AM, Trincavelli ML, Lecca D, et al. Functional characterization of two isoforms of the P2Y-like receptor GPR17: [35S]GTPgammaS binding and electrophysiological studies in 1321N1 cells. Am J Physiol Cell Physiol. 2009;297:1028–1040.
   Web of Science ®Google Scholar
• Maekawa A, Balestrieri B, Austen KF, et al. GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci USA. 2009;106:11685–11690.
   PubMed Web of Science ®Google Scholar
• Qi A-D, Harden TK, Nicholas RA. Is GPR17 a P2Y/leukotriene receptor? Examination of uracil nucleotides, nucleotide sugars, and cysteinyl leukotrienes as agonists of GPR17. J Pharmacol Exp Ther. 2013;347:38–46.
   PubMed Web of Science ®Google Scholar
• Hennen S, Wang H, Peters L, et al. Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci Signal. 2013;6:ra93.
   PubMed Web of Science ®Google Scholar
• Buccioni M, Marucci G, Dal Ben D, et al. Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17. Purinergic Signal. 2011;7:463–468.
   PubMed Web of Science ®Google Scholar
• Eberini I, Daniele S, Parravicini C, et al. In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011;25:743–752.
   PubMed Web of Science ®Google Scholar
• Temporini C, Ceruti S, Calleri E, et al. Development of an immobilized GPR17 receptor stationary phase for binding determination using frontal affinity chromatography coupled to mass spectrometry. Anal Biochem. 2009;384(1):123–129.
   PubMed Web of Science ®Google Scholar
• Calleri E, Ceruti S, Cristalli G, et al. Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. J Med Chem. 2010;53:3489–3501.
   PubMed Web of Science ®Google Scholar
• Abbracchio MP, Burnstock G, Verkhratsky A, et al. Purinergic signalling in the nervous system: an overview. Trends Neurosci. 2009;32:19–29.
   PubMed Web of Science ®Google Scholar
• Ceruti S, Villa G, Genovese T, et al. The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. Brain. 2009;132:2206–2218.
   PubMed Web of Science ®Google Scholar
• Chen J, Huang RB. Protective effect of Yulangsan polysaccharide on focal cerebral ischemia/reperfusion injury in rats and its underlying mechanism. Neurosciences (Riyadh). 2009;14:343–348.
   PubMed Web of Science ®Google Scholar
• Fumagalli M, Daniele S, Lecca D, et al. Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation. J Biol Chem. 2011;286:10593–10604.
   PubMed Web of Science ®Google Scholar
• Marucci G, Dal Ben D, Lambertucci C, et al. The G protein-coupled receptor GPR17: overview and update. ChemMedChem. 2016;11:2567–2574.
   PubMed Web of Science ®Google Scholar
• Boccazzi M, Lecca D, Marangon D, et al. A new role for the P2Y-like GPR17 receptor in the modulation of multipotency of oligodendrocyte precursor cells in vitro. Purinergic Signal. 2016;12:661–672.
   PubMed Web of Science ®Google Scholar
• Hongxia R, Orozco IJ, Su Y, et al. G protein-coupled purinergic receptor GPR17 mediates orexigenic effects of FoxO1 in AgRP neurons. Cell. 2012;149:1314–1326.
   PubMedGoogle Scholar
• Lou KJ, Writer S Getting AgRP on obesity. SciBX. 2012; [cited 2018 Nov 7]. Available from: www.nature.com/scibx/journal/v5/n28/full/scibx.2012.720.html
   Google Scholar
• Ren H, Cook JR2, Kon N3, et al. Gpr17 in AgRP neurons regulates feeding and sensitivity to insulin and leptin. Diabetes. 2015;64:3670–3679.
   PubMed Web of Science ®Google Scholar
• Obesity. World Health Organitzation. [cited 2018 Nov 7]. Available from: http://www.who.int/topics/obesity/en/
   Google Scholar
• A.M.A. Recognizes obesity as a disease. New York Times. 2013. Available from: https://www.nytimes.com/2013/06/19/business/ama-recognizes-obesity-as-a-disease.html
   Google Scholar
• Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71–82.
   PubMed Web of Science ®Google Scholar
• Accili D, Ren H G protein-coupled purinergic receptor GPR17 mediates orexgenic effects of foxo1 in AgRP neurons. US9309514 B2. 2016.
   Google Scholar
• Accili D, Ren H G protein-coupled purinergic receptor GPR17 mediates orexgenic effects of foxo1 in AgRP neurons. US20150087690 A1. 2015.
   Google Scholar
• Accili D, Ren H G protein-coupled purinergic receptor GPR17 mediates orexigenic effects of foxol in AgRP neurons. WO2013113032. 2013.
   Google Scholar
• Ceruti S, Vigano F, Boda E, et al. Expression of the new P2Y-like receptor GPR17 during oligodendrocyte precursor cell maturation regulates sensitivity to ATP-induced death. Glia. 2011;59:363–378.
   PubMedGoogle Scholar
• Ou Z, Sun Y, Lin L, et al. Olig2-targeted G-protein-coupled receptor Gpr17 regulates oligodendrocyte survival in response to lysolecithin-induced demyelination. J Neurosci. 2016;36:10560–10573.
   PubMed Web of Science ®Google Scholar
• Simon K, Hennen S, Merten N, et al. The orphan G protein-coupled receptor GPR17 negatively regulates oligodendrocyte differentiation via Galphai/o and its downstream effector molecules. J Biol Chem. 2016;291(2):705–718.
   PubMed Web of Science ®Google Scholar
• Nyamoya S, Leopold P, Becker B, et al. G-protein-coupled receptor Gpr17 expression in two multiple sclerosis remyelination models. Mol Neurobiol. 2018. DOI:10.1007/s12035-018-1146-1
   Google Scholar
• Abbracchio MP, Ciana P, Rovati G, et al. GPR17 modulators method of screening and uses thereof. US20090156521. 2009.
   Google Scholar
• Kostenis E, Spinrath A, Saarburg S, et al. Methods of identifying modulators of GPR17. US8404436B1. 2013.
   Google Scholar
• Wu B, Chien EYT, Mol CD, et al. Structures of the CXCR4 Chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010;330(6007):1066–1071.
   PubMed Web of Science ®Google Scholar
• Abbracchio MP, Eberini I, Parravicini C, et al. GPR17 modulating compounds, diagnostic and therapeutic uses thereof. WO2012059869. 2012.
   Google Scholar
• Parravicini C, Abbracchio MP, Fantucci P, et al. Forced unbinding of GPR17 ligands from wild type and R255I mutant receptor models through a computational approach. BMC Struct Biol. 2010;10:8.
   PubMed Web of Science ®Google Scholar
• Parravicini C, Ranghino G, Abbracchio MP, et al. GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors. BMC Bioinformatics. 2008;9:263.
   PubMed Web of Science ®Google Scholar
• Abbracchio MP, Battaglia MA, Eberini I, et al. GPR17 receptor modulators. US9879030 B2. 2018.
   Google Scholar
• Abbracchio MP, Battaglia MA, Eberini I, et al. GPR17 receptor modulators. WO2013167177. 2013.
   Google Scholar
• Baqi Y, Alshaibani S, Ritter K, et al. Improved synthesis of 4-/6-substituted 2-carboxy-1H-indole-3-propionic acid derivatives and structure–activity relationships as GPR17 agonists. Med Chem Commun. 2014;5:86–92.
   Google Scholar
• Köse M, Ritter K, Thiemke K, et al. Development of [(3)H]2-Carboxy-4,6-dichloro-1H-indole-3-propionic acid ([(3)H]PSB-12150): a useful tool for studying GPR17. ACS Med Chem Lett. 2014;5:326–330.
   PubMed Web of Science ®Google Scholar
• Mueller C, Pegurier C, Deligny ML, et al. (Aza)indole-, benzothiophene-, and benzofuran-3-sulfonamides. WO 2018122232. 2018.
   Google Scholar